利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

452 条记录 (耗时 0.015 秒)

    BLOOD PLATELET FLOCCULATION INHIBITOR
    45.
    发明专利
    BLOOD PLATELET FLOCCULATION INHIBITOR 失效

    公开(公告)号：JPH0327312A

    公开(公告)日：1991-02-05

    申请号：JP16192789

    申请日：1989-06-23

    申请人： DOWA MINING CO

    发明人： MAGOTA HIROMI ,  KIYO KOUGEN ,  TAKAHASHI MASAO

    IPC分类号： A61K31/05 ,  A61K31/047 ,  A61K31/16 ,  A61K31/19 ,  A61K31/215 ,  A61P7/02 ,  C07C39/21 ,  C07C59/52 ,  C07C59/68 ,  C07C59/84 ,  C07C69/017 ,  C07C271/58

    摘要： PURPOSE:To provide a blood platelet flocculation inhibitor having reduced adverse effects by containing a honokiol derivative as an active ingredient. CONSTITUTION:The objective inhibitor contains a compound of the formula [R1 and R2 are H, alkoxy, acyl, -RCOOH (R is alkylene), arylaminocarbonyl or lower alkyl; R is lower alkenyl or lower alkyl; R4 and R5 are H, hydroxy, lower alkyl, carbonyl, alkoxy or acyl] or a salt thereof as an active ingredient and a suitable carrier and/or an excipient. The inhibitor can be prepared in a form of tablets, pills, powder, granules, capsules, solutions, injections, etc. The dose is 6-1500mg/day for an adult. The compound of the formula is readily obtained by extracting from a galenical, Magnoliae Cortex, or by an organic synthetic method such as the reaction of magnolol with methyl iodide.

    DOCUMENT CREATING DEVICE
    46.
    发明专利
    DOCUMENT CREATING DEVICE 失效

    公开(公告)号：JPH02176963A

    公开(公告)日：1990-07-10

    申请号：JP33161188

    申请日：1988-12-28

    申请人： NIPPON DENKI OFFICE SYST

    发明人： TOYAMA AKIHIRO

    IPC分类号： G06F17/24 ,  A61K31/16 ,  A61K31/185 ,  A61K31/19 ,  A61K31/445 ,  C07C47/565 ,  C07C47/575 ,  C07C49/83 ,  C07C49/84 ,  C07C59/00 ,  C07C59/52 ,  C07C59/64 ,  C07C69/157 ,  C07C69/732 ,  C07C69/734 ,  C07D295/182

    摘要： PURPOSE:To easily prepare or proofread a document without such trouble that a glossary of limited terms is referred to by identifying and substituting words in a prepared document with other words. CONSTITUTION:A 1st dictionary that a storage means 14 has is stored with words which should not be used as objects of substitution for a document preparing person and a 2nd dictionary is stored with words which substitute for the words in the 1st dictionary corresponding to the words in the 1st dictionary. An identifying and substituting means 15 substitutes identified words with corresponding words is the 2nd dictionary when finding that words in the 1st dictionary are found in a document. A control means 17 supplies the document to the identifying and substituting means 15 to substitute the words in the document and handles the document after the substitution as a document to be displayed or printed out. Consequently, even a person who has no knowledge regarding the limited words can write or proofread a document without such trouble that the glossary of the limited terms is referred to.

    TYROSINEQUINASE-INHIBITING AGENT AND CARCINOSTATIC AGENT
    47.
    发明专利
    TYROSINEQUINASE-INHIBITING AGENT AND CARCINOSTATIC AGENT 失效

    公开(公告)号：JPH02142725A

    公开(公告)日：1990-05-31

    申请号：JP29365388

    申请日：1988-11-22

    申请人： NIPPON MINING CO

    发明人： GOTO YUZO ,  MAEDA HIROSHI ,  FUJIEDA SHIGEAKI

    IPC分类号： C12N9/99 ,  A61K31/165 ,  A61K31/19 ,  A61K31/215 ,  A61P35/00 ,  A61P43/00 ,  C07C59/52 ,  C07C59/90 ,  C07C69/73 ,  C07C235/34 ,  C07C235/80

    摘要： PURPOSE:To provide a tyrosinequinase-inhibiting agent and a carcinostatic agent each having reduced adverse reactions by containing as an active ingredient a hydroxyphenyl compound having a relatively simple structure and readily prepared. CONSTITUTION:A hydroxyphenyl compound of formula I or II [X is -OH, -NH2 or -OR (R is lower alkyl)] as an active ingredient is mixed with a conventional medical carrier and prepared into the objective agent by a conventional method. The compound of formula I or II is compounded with the conventional medical carrier in a ratio of 0.1-200% based on the conventional medical carrier. The agent can be prepared into a shape such as tablets, capsules, grains, syrups, suppositories, ointments or injections. The dose of the agent is 1mg-10g per adult. The compound of formula I or II includes DL-3-(2-hydroxyphenyl)lactic acid, etc.

    TYROSINEQUINASE-INHIBITING AGENT AND CARCINOSTATIC AGENT
    48.
    发明专利
    TYROSINEQUINASE-INHIBITING AGENT AND CARCINOSTATIC AGENT 失效

    公开(公告)号：JPH02142724A

    公开(公告)日：1990-05-31

    申请号：JP29365288

    申请日：1988-11-22

    申请人： NIPPON MINING CO

    发明人： GOTO YUZO ,  MAEDA HIROSHI ,  FUJIEDA SHIGEAKI

    IPC分类号： C12N9/99 ,  A61K31/165 ,  A61K31/19 ,  A61K31/215 ,  A61P35/00 ,  A61P43/00 ,  C07C59/52 ,  C07C69/732 ,  C07C235/34

    摘要： PURPOSE:To provide a tyrosinequinase-inhibiting agent and a carcinostatic agent each having reduced adverse reactions by containing as an active ingredient a hydroxyphenylpropenic acid derivative having a relatively simple structure and readily prepared. CONSTITUTION:A hydroxyphenylpropenic acid derivative of the formula [X is -OH, -NH2 or -OR (R is lower alkyl)] as an active ingredient is mixed with a conventional medical carrier and subsequently prepared into the objective agent by a conventional method. The compound of the formula is compounded with the medical carrier in a ratio of 0.1-200% based on the conventional carrier. The agent can be prepared into a shape such as tablets, capsules, granules, syrups, suppositories, ointments or injections. The dose is 1mg-10g per adult.

    PRODUCTION OF HYDROXYARYL FATTY ACIDS
    50.
    发明专利
    PRODUCTION OF HYDROXYARYL FATTY ACIDS 失效

    公开(公告)号：JPH01106843A

    公开(公告)日：1989-04-24

    申请号：JP26478487

    申请日：1987-10-20

    申请人： NIPPON OILS & FATS CO LTD

    发明人： KOBASHI HITOSHI ,  SEI NOBUHIKO ,  KADOMA YOSHIHITO

    IPC分类号： C07C51/353 ,  B01J21/16 ,  C07B61/00 ,  C07C51/50 ,  C07C59/52 ,  C07C67/347 ,  C07C69/732

    摘要： PURPOSE:To obtain the titled compounds which are antioxidants, corrosion inhibitors, etc., with a stable hue of a light color, by reacting a hydroxyaryl compound with unsaturated fatty acids in the presence of activated clay as a catalyst, adding a specific compound and removing the above-mentioned catalyst. CONSTITUTION:A hydroxyaryl compound in an amount of preferably excess of unsaturated fatty acids is thermally reacted with the unsaturated fatty acids in the presence of activated clay as a catalyst at 125-225 deg.C, preferably 160-200 deg.C in, e.g. an autoclave. In the second stage, an oxyacid of phosphorus or a salt thereof is then added to the reaction solution containing the abovementioned hydroxyaryl fatty acids and reacted at a temperature within the range of normally 80-100 deg.C. The afore-mentioned catalyst contained in the reaction solution is subsequently removed by a filtration method, etc., to afford the aimed compounds. Furthermore, the amount of the added oxyacid of phosphoric acid or salt thereof is preferably within the range of 0.5-2wt.%.